MannKind Corporation has announced the initiation of the Phase 4 INHALE-3 study of its Afrezza DPI in type 1 diabetes patients. The trial is expected to enroll approximately 120 type 1 diabetes patients who currently use an insulin pump.
Over the course of the 17-week study, one group will continue their usual insulin delivery method, and another group will use basal insulin injections plus Afrezza. Both groups will use continuous glucose monitoring, and both will participate in a 13-week extension using basal insulin plus Afrezza.
MannKind CEO Michael Castagna commented, “This large study is planned to assess improvement in mealtime glycemic control, which continues to be a serious challenge for the majority of people living with type 1 diabetes. INHALE-3 will study the effect of Afrezza on mealtime control, which has a time-action profile that closely mimics that of physiologic insulin in the first 120 minutes after a meal.”
Read the MannKind Corporation press release.
